ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,460.48
      -0.41%
      US Tech 100
      19,181.60
      -0.43%
      Dow Jones
      39,118.86
      -0.12%
      Brent Oil
      84.85
      0.00%
      Bitcoin
      61,472.85
      0.96%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Galectin Therapeutics Inc (GALT)

      7. Galectin Therapeutics Inc (GALT) News

      GALT

      Galectin Therapeutics (GALT)

      Galectin Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:GALT
      DateTimeSourceHeadlineSymbolCompany
      03/16/202211:42AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      03/01/20228:04AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      02/04/20226:24PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      02/01/202210:14AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/25/20224:53PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/25/20224:44PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/25/20224:36PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/25/20224:30PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/25/20224:25PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/25/20224:23PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/25/20224:20PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/24/20228:43AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/19/202211:19AMEdgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:GALTGalectin Therapeutics Inc
      01/19/202211:03AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/18/20228:55AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/18/20228:08AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/13/20223:42PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/06/20228:00AMGlobeNewswire Inc.Galectin Therapeutics to Present at the H.C. Wainwright BioConnect ConferenceNASDAQ:GALTGalectin Therapeutics Inc
      01/03/20227:52AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      12/21/20218:00AMGlobeNewswire Inc.Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. UihleinNASDAQ:GALTGalectin Therapeutics Inc
      12/21/20217:51AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GALTGalectin Therapeutics Inc
      12/15/20214:47PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      12/15/20214:35PMEdgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:GALTGalectin Therapeutics Inc
      12/15/20214:26PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      12/13/20218:00AMGlobeNewswire Inc.Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual MeetingNASDAQ:GALTGalectin Therapeutics Inc
      12/06/20212:10PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      12/06/202112:43PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      12/03/202112:00PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GALTGalectin Therapeutics Inc
      12/01/20219:43AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      11/15/20214:44PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:GALT

      Your Recent History

      BIT
      F39158
      Vontobel Financial Produ...
      Delayed Upgrade Clock